IAVI

NFID Announces 2024 Recipients of Prestigious Awards

Retrieved on: 
Tuesday, April 9, 2024
RN, Maxwell Finland Award, COVAX, Health equity, HIV, Biomedical Research, Health, Patient, Epidemic, Infection, Rockefeller Foundation, Vaccine, Ageing, AIDS, International, Education, Policy, Master of Science, Woman, Gavi, World Health Organization, Immunization, Safety, Disease, Global health, Public, Research, Death, Mentorship, NFID, MPH, National Academy of Medicine, CPNP, COVID-19, IAVI, National academy, Developed country

BETHESDA, Md., April 9, 2024 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the 2024 recipients of the prestigious NFID awards honoring outstanding individuals who have made significant and lasting contributions to public health through leadership, scientific achievement, philanthropy, and policy work. The following awards will be presented at the 2024 NFID Awards Gala in Washington, DC in September 2024:

Key Points: 
  • BETHESDA, Md., April 9, 2024 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the 2024 recipients of the prestigious NFID awards honoring outstanding individuals who have made significant and lasting contributions to public health through leadership, scientific achievement, philanthropy, and policy work.
  • The following awards will be presented at the 2024 NFID Awards Gala in Washington, DC in September 2024:
    Seth F. Berkley, MD, of the Pandemic Center of Brown University, will receive the 2024 Jimmy and Rosalynn Carter Humanitarian Award in recognition of his work as an innovative entrepreneur, a pioneer in global health, and a champion of equitable access to vaccines.
  • The awards will be presented at the 2024 NFID Awards Gala and Silent Auction, a black-tie fundraising event scheduled for September 19, 2024, in Washington, DC.
  • All contributions support the NFID mission to educate the public and healthcare professionals on the prevention and treatment of infectious diseases.

ObvioHealth and Oracle Life Sciences Expand Partnership Globally

Retrieved on: 
Thursday, February 8, 2024
Oracle Corporation, Partnership, IAVI, MySQL, Data management, Safety, American Opportunity Tax Credit, Multimedia, Clinical trial, Zaire ebolavirus, Patient, Java, Pharmaceutical industry

NEW YORK, Feb. 8, 2024 /PRNewswire/ -- ObvioHealth, a global digital clinical trials company, and Oracle Life Sciences are expanding their partnership globally following the results of a year-long, successful effort launching trials in Asia Pacific. The collaboration will enable the efficient capture, integration, and analysis of multi-source clinical trial health data anywhere in the world—from participants, clinicians, devices, and labs. 

Key Points: 
  • To integrate diverse data in decentralized clinical trials and offer enhanced multi-site, multi-lingual integrations
    NEW YORK, Feb. 8, 2024 /PRNewswire/ -- ObvioHealth , a global digital clinical trials company, and Oracle Life Sciences are expanding their partnership globally following the results of a year-long, successful effort launching trials in Asia Pacific.
  • The expanded partnership coincides with the release of ObvioGo® 2.0, the next generation of ObvioHealth's digital clinical trial platform and mobile app.
  • "The expansion of ObvioGo, in partnership with Oracle, is an important step towards truly globalizing digital trials," said Ivan Jarry, CEO of ObvioHealth.
  • "Our newly expanded partnership with ObvioHealth will bring greater access, equity, and data availability to clinical trials globally," said Drew Zwiebel, Global Vice President, Alliances & Channels at Oracle Life Sciences.

Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 14, 2023
VLP, IAVI, Antigen, RSV, Senior, XBB, Neuraminidase, Investment, Human, Hemagglutination, Research, Completeness, Vaccine, G&A, Infection, International AIDS Vaccine Initiative, R, Growth, Neutralizing antibody, Doctor of Philosophy, SARS-CoV-2, Congress, RBD, Cryptocurrency

SEATTLE, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • In August 2023, Icosavax provided an update from its Phase 1b extension trial of IVX-121 against RSV in older adults.
  • Prior to Icosavax, Antu held roles of increasing responsibility at GreenLight Biosciences, International Aids Vaccines Initiative (IAVI), Novartis Vaccines & Diagnostics, and GSK Vaccines.
  • Research and development expenses include non-cash stock-based compensation expenses of $2.7 million for the three months ended September 30, 2023.
  • General and administrative expenses include non-cash stock-based compensation expenses of $3.9 million for the three months ended September 30, 2023.

AuraVax Therapeutics Appoints Two Healthcare Veterans to its Board of Directors

Retrieved on: 
Tuesday, November 28, 2023
P&G, IAVI, International Society, Licensure, Research, GM, Therapy, Medical Center, ALS, Sanofi Pasteur, American Academy, Merck, Vaccine, Merck & Co., Antibody, Growth, New business development, Knowledge, Bangladesh Technical Education Board, IGM, Hamilton College, Pharmaceutical industry, Sanofi, Biotechnology, Microbiology, Economics, Medication

HOUSTON, Nov. 28, 2023 /PRNewswire/ -- AuraVax Therapeutics, Inc., a biotechnology company developing novel immunotherapies to prevent and treat respiratory viruses, today announced that Thomas Finn and John Shiver have joined the company's board of directors. They will serve with Laurence Cooper who is the chair of AuraVax's board.

Key Points: 
  • They join AuraVax at an exciting time as our lead product, NanoSTING-001, advances to clinical testing.
  • Finn serves as a Board member of Cincinnati Children's Medical Center and is Chair of their Research Committee.
  • He also serves as a Board member for Eikonoklastes Therapeutics, a Biotech company developing gene therapy for amyotrophic lateral sclerosis.
  • Shiver also serves as a board member of Icosavax Inc and IAVI Boards of Directors.

Monoclonal Antibody Diagnostic Reagent Global Market Report 2022: Extensive R&D Efforts to Develop Novel Therapies Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 8, 2022
Health, General Health, Diagnosis, Infection, Chinese cuisine, Antibody, American Cancer Society, Growth, Patient, Application, Hormone, CAGR, Degenerative disease, CFDA, Biomedical Research, Population, Survival, Cancer, HIV/AIDS, International Council, Harmonization, Hepatitis, COVID-19, Enzyme, ELISA, Fluorophore, Overalls, Ageing, IAVI, Prevalence, Herpes simplex, International, Sale, Conditional sentence, Chlamydia, Vaccine, Pharmaceutical industry, Neutralizing antibody

The "Monoclonal Antibody Diagnostic Reagent Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Tests and Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Monoclonal Antibody Diagnostic Reagent Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Tests and Application" report has been added to ResearchAndMarkets.com's offering.
  • The rising prevalence of cancer & other chronic diseases, extensive R&D efforts to develop novel therapies, and the presence of a strong pipeline of drugs under trial are the major factors boosting the market growth.
  • Such factors are stimulating the uptake of mAbs, which is contributing to the monoclonal antibody diagnostic reagent market growth.
  • Based on application, the monoclonal antibody diagnostic reagent market is segmented into hormones diagnosis, tumor monitoring, virus detection, and others.

Mallinckrodt Announces Appointment of Susan Silbermann to its Board of Directors

Retrieved on: 
Thursday, October 6, 2022
U.S. Securities and Exchange Commission, The Company, Writer, NGO, SEC, Faculty of Human, Social, and Political Science, University of Cambridge, General manager, Ophthalmology, Emerging market, Vaccine, Education, Politics, Annual report, Patient, Tufts University, Commercial, IAVI, Region, Risk, Senior, Private Securities Litigation Reform Act, Infection, Social, Administration, Company, Trade, Analgesic, Neurology, Ajman Specialty General Hospital, Board, International business, Safety, Immunotherapy, Board of directors, Rheumatology, HIV-AIDS, Autoimmunity, COVID-19, Nephrology, Public health, Management, Pharmaceutical industry, Marketing, Pfizer, Biology, New York University, Mallinckrodt

DUBLIN, Oct. 6, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has appointed Susan Silbermann to its Board of Directors, effective October 5, 2022.

Key Points: 
  • DUBLIN, Oct. 6, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has appointed Susan Silbermann to its Board of Directors, effective October 5, 2022.
  • With the addition of Ms. Silbermann, the Mallinckrodt Board will expand to nine directors, eight of whom are independent.
  • "Susan is a highly respected and deeply experienced global executive in the healthcare industry, and we are pleased to welcome her to Mallinckrodt's Board," said Paul Bisaro, Chairman of the Mallinckrodt Board of Directors.
  • "I am excited to join the Mallinckrodt Board at this transformative moment for the Company," said Ms. Silbermann.

Clover Appoints Nicholas Jackson, Ph.D., as President of Global Research and Development

Retrieved on: 
Tuesday, February 1, 2022
Forward-looking statement, SCB-2019, University, Development, Sanofi Pasteur, Technology, Research, Pfizer, COVID-19, CpG, D, CEPI, Center, Hygiene, Global Research, University of Warwick, Vaccine, GLOBE, Bachelor of Science in Biomedical Engineering, Epidemic, Severe acute respiratory syndrome coronavirus 2, London School of Hygiene & Tropical Medicine, Tropical medicine, IAVI, Oxford Brookes University, GlaxoSmithKline, Pharmaceutical industry, Clover, Trimer, Science

(Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced the appointment of Nicholas Jackson, Ph.D., as President of Global Research and Development.

Key Points: 
  • (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced the appointment of Nicholas Jackson, Ph.D., as President of Global Research and Development.
  • "I am honored to join Clover and look forward to helping expand its global R&D capabilities and innovative pipeline of vaccines and oncology therapies.
  • Prior to his work at CEPI, Dr. Jackson was Vice President, Head of Global Research for Sanofi Pasteur, responsible for leading vaccine research and early development activities globally.
  • Before Sanofi Pasteur, Nicholas held vaccine and immunotherapeutic development roles at Pfizer, IAVI and GlaxoSmithKline, where he oversaw R&D programs, global clinical trials and collaborations.

IAVI Welcomes Marion F. Gruber as Vice President, Public Health and Regulatory Science

Retrieved on: 
Tuesday, January 18, 2022
AIDS, Health, Infectious Diseases, Other Health, Research, Science, Biotechnology, Research, Vaccine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Probability, COVID-19, Severe acute respiratory syndrome coronavirus 2, Licensure, Safety, Knowledge, CEO, World, Leadership, Public health, Pandemic, Global health, HIV, Infection, Efficiency, WHO, Therapy, Food, World Health Organization, FDA, Policy, Tuberculosis, Acquisition, Pharmaceutical industry, Review, IAVI

IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, is very pleased to announce the appointment of Marion F. Gruber, Ph.D., M.S., as Vice President, Public Health and Regulatory Science.

Key Points: 
  • IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, is very pleased to announce the appointment of Marion F. Gruber, Ph.D., M.S., as Vice President, Public Health and Regulatory Science.
  • IAVI is thrilled to welcome Dr. Gruber, with her considerable regulatory expertise and leadership experience, said Mark Feinberg, M.D., Ph.D., IAVI president and CEO.
  • Dr. Gruber will lead IAVIs strategic engagement with key external organizations and stakeholders working to shape scientific, regulatory, and public health policies to advance global health product development and access-enabling efforts.
  • In addition, she will devise regulatory science and public health strategies to maximize the efficiency, effectiveness, and probability of success for IAVIs own product development and implementation efforts.

GreenLight (ENVI) and IAVI begin work on Omicron variant-adapted COVID-19 vaccine candidate

Retrieved on: 
Friday, December 3, 2021
Private Securities Litigation Reform Act, Forward-looking statement, Green-light, Tuberculosis, ENVI, Health, Clinical trial, Solution, IAVI, Therapy, Agriculture, Vaccine, COVID-19, Omicron, View, Risk, Tropical disease, RNA, RNA transfection, Antibody, Infection, NEW, Multimedia, African, HIV, Animal, Pharmaceutical industry

BOSTON and NEW YORK, Dec. 3, 2021 /PRNewswire/ --GreenLight Biosciences (ENVI) and IAVI, a nonprofit scientific research organization, today announced work on a messenger RNA vaccine candidate to tackle the COVID-19 Omicron variant.

Key Points: 
  • BOSTON and NEW YORK, Dec. 3, 2021 /PRNewswire/ --GreenLight Biosciences (ENVI) and IAVI, a nonprofit scientific research organization, today announced work on a messenger RNA vaccine candidate to tackle the COVID-19 Omicron variant.
  • "The highly mutated Omicron variant may be partially capable of eluding existing vaccines, so rapid adaptation is an urgent priority," said GreenLight CEO Andrey Zarur.
  • We will be testing a new candidate vaccine shortly in preclinical models.
  • The flexibility of the messenger RNA platform has allowed GreenLight to advance new variant-adjusted vaccine candidates.

GreenLight Biosciences (ENVI) partners with IAVI to accelerate COVID-19 vaccine trial in Africa

Retrieved on: 
Tuesday, November 30, 2021
Private Securities Litigation Reform Act, Forward-looking statement, Snakebite, Coalition for Epidemic Preparedness Innovations, Green-light, Tuberculosis, ENVI, African Union, Health, Partnership, Severe acute respiratory syndrome coronavirus 2, Epidemic, Clinical trial, Coalition, IAVI, Therapy, Vaccine, COVID-19, Agriculture, View, Lassa fever, Risk, Union, Africa Centres for Disease Control and Prevention, Tropical disease, RNA, Organization, RNA transfection, Antibody, Infection, Multimedia, Disease, HIV, Pharmaceutical industry

NEW YORK, Nov. 30, 2021 /PRNewswire/ -- GreenLight Biosciences has partnered with the non-profit scientific research organization IAVI to work together on a Phase I clinical trial in Africa.

Key Points: 
  • NEW YORK, Nov. 30, 2021 /PRNewswire/ -- GreenLight Biosciences has partnered with the non-profit scientific research organization IAVI to work together on a Phase I clinical trial in Africa.
  • IAVI and its partners were among the first to conduct HIV vaccine clinical trials in Africa, and since then, IAVI has sponsored more than 60 vaccine and biologics clinical trials in 13 countries.
  • GreenLight will provide its vaccine candidate for the trial and will make preparations for large-scale manufacturing of the vaccine.
  • This partnership aims to accelerate the timeline for manufacturing and deployment of GreenLight's COVID-19 vaccine candidate to Africa and potentially for export from Africa.